Navigation Links
Genmab Announces 2007 First Half Year Results
Date:8/22/2007

Summary: Genmab Reports Results for the Six Month Period Ended June 30,

2007

COPENHAGEN, August 22 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today results for the six month period ended June 30, 2007. During this period, Genmab reported the following results:

Genmab's revenues were DKK 279.6 million (approx. USD 50.7 million) for the first half of 2007. In the same period of 2006, Genmab recognized DKK 74.3 million (approx. USD 13.5 million) in revenues.

An Operating Loss of DKK 118.9 million (approx. USD 21.6 million). This compares to an Operating Loss of DKK 187.5 million (approx. USD 34.0 million) reported for the corresponding period of 2006.

Net Financial Income totaled DKK 31.8 million (approx. USD 5.8 million), compared to Net Financial Expenses of DKK 2.3 million (approx. USD 0.4 million) in the first six months of 2006. Net Financial Income has benefited from the higher average cash position, whereas the negative net financial income reported for the first half of 2006 was impacted by increasing interest rates and weakening of the USD against the DKK.

A Net Loss of DKK 87.0 million (approx. USD 15.8 million) compared to a Net Loss of DKK 189.8 million (approx. USD 34.4 million) for the same period in 2006. The Net Loss per share was DKK 2.01 (approx. USD 0.36) for the first half of 2007 compared to DKK 4.96 (approx. USD 0.90) in the first half of 2006.

Genmab ended the six month period with a cash position of DKK 3.980 billion (approx. USD 722 million), which is a net increase of DKK 2.256 million (approx. USD 409.4 million) from the end of 2006.

Highlights

During the second quarter of 2007, Genmab achieved a number of business and scientific milestones, as follows:

On June 29, Genmab regained all rights to HuMax-CD4(R) (zanolimumab) from Merck Serono S.A. and announced final data from the HuMax-CD4 Phase II data in cutaneous T-cell lymphoma (C
'/>"/>

SOURCE Genmab A/S
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)...DOVA, Calif., Nov. 5 The...ier of innovative products for processing and stor...he first quarter of fiscal 2010. ,, For the qua...d revenues of $5.2 million, a 15 percent increase ... a year ago. The Company said the key contributors...
(Date:11/5/2009)...., Nov. 5 Transgenomic, ...nancial results for the quarter ended September 30...ted in the tables that follow. ,, Third Quarte...366,000 or $0.01 per share for the third quarter o....01 per share for the third quarter of 2008. ,...
(Date:11/5/2009)... Calif., Nov. 5 Cepheid ...es will be speaking at the following investor conf...webcast. , , Credit Suisse Healthc...day, 12 November, 2009 at 10 a.m. Mountain Time, ...London, England, Tuesday, 1 Decemb...
(Date:11/5/2009)... CA, November 5, 2009 Se... using proprietary taste receptor-based technologi...od, beverage, and ingredient supply industries, to...cial results for the third quarter ended September...rd quarter of 2009, compared to $4.0 million for t...
Breaking Biology Technology:ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 4ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 5ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 7ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 8Transgenomic, Inc. Reports Third Quarter 2009 Results 2Transgenomic, Inc. Reports Third Quarter 2009 Results 3Transgenomic, Inc. Reports Third Quarter 2009 Results 4Transgenomic, Inc. Reports Third Quarter 2009 Results 5Transgenomic, Inc. Reports Third Quarter 2009 Results 6Transgenomic, Inc. Reports Third Quarter 2009 Results 7Cepheid to Webcast Upcoming Financial Presentations 2SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14
...IN LAKES, N.J., March 13 Medco Health,Solutions, ...eed to sell $300,million aggregate principal amoun... and $1.2 billion aggregate principal amount of 7-...underwritten public offering. Citi,J.P. Morgan Sec...arclays,Capital Inc. are acting as representatives...
... Generation Treatment from Abbott Shows No Thrombo...ary Clinical Study of Thirty Patients, ABBOTT PAR...cet from ABSORB, the world,s first clinical trial ...e treatment of coronary artery,disease, demonstrat...t,lesion revascularizations (retreatment of a dise...
...EY, Calif., March 13 Nile Therapeutics,Inc. (OTC ...quarter and,full year financial results for 2007. ...e conference call from the investor relations sect... . The webcast will remain available on,the compan...ll., For the fourth quarter of 2007, Nile reporte...
Other Biology Technology:Medco Issues $1.5 Billion of Senior Notes 2Medco Issues $1.5 Billion of Senior Notes 3The Lancet Publishes Results From World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent 2The Lancet Publishes Results From World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent 3The Lancet Publishes Results From World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent 4Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 2Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 3
(Date:11/5/2009)...ining grant in the amount of $2,756,719 by the Nat...duation Education and Research Training (IGERT) pr... to Kent State. The grant, which is funded under t... runs through 2014. , The grant funds an IGERT p...e sensing (EARS). The purpose of the program is to...
(Date:11/4/2009)...g Beach and Riverside are responsible for a signif...and the true impact of air pollution and ship emis...d, according to researchers at the University of S...pears in an online edition of the American Journa...f all childhood asthma cases in Long Beach and six...
(Date:11/4/2009)... DNA codes, or genomes, of the famed fugu (or puff...10K Project, an international effort to build an i...ecies of animals for conducting comparative studie..., Participating in The Genome 10K project, descri... of the Journal of Heredity , are 70 leading scie...
Breaking Biology News(10 mins):Kent State receives $2.7 million NSF training grant for environmental aquatic resource sensing 2USC study finds big air pollution impacts on local communities 2Singapore scientists join international study of 10,000 vertebrates' genomes 2Radiology Benefit Management Could Save Medicare up to 2418 Billion Over 10 Years 51941 1Radiology Benefit Management Could Save Medicare up to 2418 Billion Over 10 Years 51941 2Radiology Benefit Management Could Save Medicare up to 2418 Billion Over 10 Years 51941 3Scientists Reverse Muscular Dystrophy in Mice 51938 1Scientists Reverse Muscular Dystrophy in Mice 51938 2Scientists Reverse Muscular Dystrophy in Mice 51938 3Arcadian Chairman and Chief Executive Officer Robert Fahlman to Present at Focus on Healthcare Conference in New York City 51935 1
...y the National Institute on Drug Abuse (NIDA), par...he first time identified genes that might increase...reakthrough research was conducted by Dr. George U...m led by Dr. Jed Rose at the Center for Nicotine a...edical Center. , The study, published in the journ...
... of Allergy and Infectious Diseases (NIAID), part ...announced it is awarding $23 million per year for ... for Influenza Research and Surveillance. Collecti...rveillance program internationally and in the Unit...key areas, including understanding how the virus c...
...n that reduced calorie intake can increase health ...ity of California) and his collaborators* have dis... can still induce many of the health and longevity...tly, this also includes anti-cancer effects. , Th...creening technique to find drugs which mimic this ...
Other Biology News:NIDA study identifies genes that might help some people abstain from smoking 2NIAID expands capability for influenza research and surveillance 2NIAID expands capability for influenza research and surveillance 3NIAID expands capability for influenza research and surveillance 4It's never too late to get it back! Aging interrupted 2
Luminex 100 IS System from Luminex Corporation
GIBCO Water distilled from Invitrogen
Rabbit Anti-Bovine Respiratory Syncytial Virus Bovine Respiratory Syncytial Virus Antibody, Unconjugated from ABR-Affinity BioReagents
Rabbit Anti-MacMarcks Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
Biology Products: